科華生物(002022.SZ):子公司新型冠狀病毒核酸檢測項目獲地方政府專項資金支持
格隆匯2月16日丨科華生物(002022.SZ)公佈,近日,公司控股子公司西安天隆科技有限公司(“西安天隆”)、蘇州天隆生物科技有限公司(“蘇州天隆”)分別收到地方政府通知,主要內容如下:
1、西安天隆收到西安市科學技術局和西安市財政局下發的《關於下達西安市新型冠狀病毒肺炎疫情應急防治科技專項(第一批)項目的通知》(市科發【2020】10號),西安天隆“新型冠狀病毒核酸檢測產品規模化生產及應急推廣應用”課題項目獲得財政資金專項支持50萬元;
2、蘇州天隆收到蘇州市財政局和蘇州市發展和改革委員會下發的《關於下達核酸檢測試劑和疫苗生產研發企業專項資金的通知》(蘇財建【2020】9號),蘇州天隆的“新型冠狀病毒(2019-nCoV)核酸檢測試劑盒及配套核酸提取試劑盒產業化”項目獲得財政資金專項支持200萬元。
以上專項資金補助與公司日常經營活動相關,未來是否持續發生存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.